Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Advisory committee meeting scheduled for atosiban NDA review

April 8, 1998

Discovery Laboratories begins phase Ib trials of ST-630

April 8, 1998

Phase Ib results reported for allosteric Hb modifier RSR13

April 7, 1998

TNT will assess further benefits of Lipitor

April 7, 1998

Elevated plasma P-selectin levels are associated with hypercholesterolemia

April 7, 1998

Baxter suspends study of HemAssist in U.S. trauma patients; other trials continue

April 6, 1998

Highly potent GH secretatogues discovered by Merck & Co.

April 6, 1998

Agents for hyperlipidemia under investigation at HMR

April 6, 1998

FDA approves Actonel for Paget's disease

April 3, 1998

Redux adverse effects reviewed at ACC

April 3, 1998

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...